biomed devic servic
price close busi april
invas medic devic heart valv therapi
includ tissu valv mechan valv
ew stay favorit rel basi wait
group valuat retrac pt
bottom line solid ration posit commentari regard potenti
pathway back normalci surmis ew goe eye covid storm
come side whenev might firm think
one strongest best-posit med-tech compani world consequ
would overweight ew rel basi large-cap med-tech stock
said would wait market retrac add posit absolut
basi uncomfort med-tech valuat broadli speak wit
estim compani obvious flux present base
current consensu large-cap med-tech trade price-to-earnings compar
peak pre-covid feb previou multi-decad peak sept
contrast past decad go back earli large-
cap med-tech trade peak/trough rang great recess
favor higher multipl overal med-tech reason
written extens think current valuat
group fail reflect enough covid-rel risk
reason favor ew rel basi howev quit straightforward
think compel ew top large-cap peer term target market viabil
size penetr import provid patient word tavr
procedur come back first ampl left portend double-
digit growth rate return ew market technolog differenti
pipelin tavr ew favor firm mitral tricuspid
portfolio well leverag margins/ep suffer revenu
suppress covid ew proven abil leverag tavr revenu growth
eventu tmtt portfolio well drive strong
well om expans still see low-to-mid rang medium long-
term latter suffer near-term covid caus greater rel pullback
tavr revenu rel critic revenu howev long term still
under-penetrated tavr best-in-class platform compel tmtt portfolio
think pay dividend beyond maintain buy ew
ad posit valuat settl across group
tavr tavr continu growth engin ew get back
semblanc normalci post-covid view strength display
sale y/i growth vs covid-unadjust
estim pre-covid beat street consensu covid adjust
manag note strong earli march run commensur
robust level us procedur volum fell precipit due
sapien ultra roll-out continu strong repres total
us eu tavr volum quarter firm paus proctor center
arent alreadi train sapien pandem manag remain
bullish releas two-year data see takeaway note
tavr demonstr non-inferior versu savr stress studi
small patient cohort tavr still numer superior us sale
still strong quarter notwithstand end-of-quart covid impact grow
ou growth mid-teen notabl japan saw good
meaning impact manag warn could
chang might week behind unit state
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object
view compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
epidemiolog curv look forward manag assum
covid impact tavr procedur sever follow
gradual recoveri resembl origin expect
sale manag project tavr flat vs
rang y/i vs previou expect ew still confid
assumpt opportun
tmtt updat ew still earli inning push develop
market leader global transcathet mitral/tricuspid therapi market
effect put tarp field previous
announc ew paus tricuspid trial decis resum
enrol made investig manag expect
least two quarter see tmtt one last procedur
come back given quit resourc intens requir gener
anesthesia post-op icu stay revenu tmtt quarter
split differ estim pre-covid
street consensu manag trim revenu
expect compani expect signific
neg impact recoveri begin firm reiterate
view tmtt global opportun reach think
aggress optimist ew inde highli instrument
market develop well key player drive long-term
market growth expect long believ
market theoret bigger tavr also opin market
take even longer tavr tip restart clinic work
deliv four pivot trial tmtt critic market
guidanc updat impact ew updat
guidanc light impact notabl manag made clear
base case condit improv would look
low end rang addit firm made clear
estim take account possibl second wave fall
promin scientist suggest could occur manag expect
revenu rang compar previou
estim would highlight guidanc origin
revenu increas edward expect
adjust ep compar previou estim
would highlight origin
firm project total revenu rang
wider usual guidanc rang import keep mind
public compani elect withdraw guidanc complet
compani transpar number base
assumpt impact sale sever
second quarter follow gradual recoveri third quarter fourth
quarter better resembl origin expect sale
believ timelin could aggress notwithstand
possibl whole second wave covid patient fall edward
treat critic ill patient hospit need
revenu help reduc mortal structur heart patient make
revenu procedur case tavr could see
resurg base fairli resourc light patient condit
like face high mortal left untreat studi suggest patient
wait aortic valv replac mortal risk one month
three six hospit need balanc mortal data
versu prevalence/risk covid commun could see
signific geograph differ tavr procedur resumpt
buy unchang target price april
biomed devic servic
deriv price target appli price-to-earnings
pro forma ep estim
buy unchang target price april
biomed devic servic
p/e/g valuat financi metric use median large-cap med-tech comp group price-to-earnings multipl forma ep growth p/e/g multipl price-to-earnings multipl forma mo lifesci averag implant center total unit total ew ww tavi revenu ex growth averag total unit total ww tavi revenu growth averag total unit total ww tavi revenu growth player ww tavi revenu ww implant patient popul player tavi ww revenu market figur tavr us market model
buy unchang target price april
biomed devic servic
symptomat patient year year year american age aortic age sever sever symptomat etiolog s/ ssa primari etiolog pe patient yr severe/symptomat ssa pe patient yr yr severe/symptomat tam ssa pe patient consid high risk surgeri consid intermedi risk surgeri consid risk surgeri consid high risk surgeri consid intermedi risk surgeri consid risk surgeri tavr market opportun tavr market opportun figur tavr us market share
buy unchang target price april
biomed devic servic
edward lifesci implant averag implant total unit asp ew us revenu averag total unit asp us revenu averag total implants- implant unit asp us revenu player us revenu us implant address patient penetr us tavr market figur tavr eu/row market share
buy unchang target price april
biomed devic servic
detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact inform
appear front page report
buy unchang target price april
biomed devic servic
million except per share revenu gross oper expens incom pre-tax incom tax interest exp eitf add-back net incom share ep forma ex ia margin analysi gross margin pro sale sale y/i revenu growth growth growth incom pro forma incom forma ex-one-tim ia figur revenu model part
buy unchang target price april
biomed devic servic
heart valv aortic/mitr replacement/repairaort tavi sapien product royalti us total tavi mitral/trucuspid total tmvr/re total transcathet valv therapi surgic heart valv therapytissu repair surgic heart valv cardiac surgeri cardiac surgeri total surgic hv cs surgic valv consign total surgic hv/c revenu critic hemodynam pressur critic vascular vascular casm total critic vascular revenu pro forma total revenu figur revenu model part
buy unchang target price april
biomed devic servic
